{"title":"晚期多发性硬化症药物发展前景看好。","authors":"Troy Kish","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Developing drugs with enhanced safety profiles and improving treatment affordability are vital for patients with MS. The author reviews some encouraging new agents in late-stage development.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"43 12","pages":"750-772"},"PeriodicalIF":0.0000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281141/pdf/ptj4312750.pdf","citationCount":"0","resultStr":"{\"title\":\"Promising Multiple Sclerosis Agents In Late-Stage Development.\",\"authors\":\"Troy Kish\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Developing drugs with enhanced safety profiles and improving treatment affordability are vital for patients with MS. The author reviews some encouraging new agents in late-stage development.</p>\",\"PeriodicalId\":38773,\"journal\":{\"name\":\"P and T\",\"volume\":\"43 12\",\"pages\":\"750-772\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281141/pdf/ptj4312750.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"P and T\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"P and T","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
Promising Multiple Sclerosis Agents In Late-Stage Development.
Developing drugs with enhanced safety profiles and improving treatment affordability are vital for patients with MS. The author reviews some encouraging new agents in late-stage development.
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
